Xenon Pharmaceuticals (XENE) EBITDA (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of EBITDA data on file, last reported at -$103.8 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$103.8 million, down 61.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$387.9 million (down 49.56% YoY), and the FY2025 annual result was -$373.1 million, down 33.57% from the prior year.
• EBITDA rose to -$103.8 million in Q1 2026 per XENE's latest filing, from -$109.8 million in the prior quarter.
• Over five years, EBITDA peaked at -$17.4 million in Q1 2022 and troughed at -$109.8 million in Q4 2025.
• A 5-year average of -$60.0 million and a median of -$53.7 million in 2023 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 8.16% in 2022 and fell as far as 231.89% in 2022.
• A 5-year view of EBITDA shows it stood at -$43.3 million in 2022, then retreated by 23.92% to -$53.7 million in 2023, then slumped by 44.29% to -$77.5 million in 2024, then slumped by 41.68% to -$109.8 million in 2025, then increased by 5.39% to -$103.8 million in 2026.
• Business Quant data shows XENE's EBITDA at -$103.8 million in Q1 2026, -$109.8 million in Q4 2025, and -$90.5 million in Q3 2025.